Reducing the expression of the protein TOM1 in mouse models of Alzheimer's disease increased the pathology, exacerbated cognitive problems, and raised levels of inflammation in the brain. Restoring TOM1 reversed the effects. Findings suggest a new therapeutic target for treating dementia.